AtriCure
ATRC
213 hedge funds and large institutions have $1.82B invested in AtriCure in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 85 increasing their positions, 62 reducing their positions, and 35 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 62
0.21% more ownership
Funds ownership: 95.68% → 95.89% (+0.21%)
3% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 35
2% less funds holding
Funds holding: 217 → 213 (-4)
37% less capital invested
Capital invested by funds: $2.89B → $1.82B (-$1.07B)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$16.3M |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$10.5M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.46M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$9M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$8.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$23.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$12.9M |
| 3 |
FAM
Fred Alger Management
New York
|
-$11.6M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$10.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.19M |
ATRC Hedge Fund Activity: Q2 2022 in Review
213 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q2 2022, worth a combined $1.82B — down 37% from $2.89B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ATRC and 34 opened new positions — a net loss of 1 holder — while 62 trimmed existing stakes and 85 added.
The largest buyer was Champlain Investment Partners, adding an estimated $16.3M. The largest seller was Millennium Management, cutting an estimated $23.7M.
- 213 institutional investors held AtriCure (ATRC) as of Q2 2022, down from 217 in Q1 2022.
- Funds reported $1.82B of AtriCure stock for Q2 2022, down 37% quarter-over-quarter.
- 34 funds opened new AtriCure positions in Q2 2022 and 35 closed out, a net change of -1 holder.
- The largest AtriCure buyer in Q2 2022 was Champlain Investment Partners, an estimated $16.3M added.
- The largest AtriCure seller in Q2 2022 was Millennium Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q2 2022.